The global array instruments market is anticipated in a report by Transparency Market Research (TMR) to find companies making substantial investment in system automation for reaping rich benefits in terms of revenue growth and ease of operation. Some of the prominent names of the market, viz. Molecular Devices, Affymetrix, Inc., and Illumina, Inc. could make their presence known in the industry. Merger and acquisition could be commonly adopted by players as a primary business strategy for securing a strong foothold in the market. In May 2018, Edico Genome was acquired by Illumina, Inc. for acceleration of genomic data analysis.
TMR envisions the global array instruments market to expand to a US$1.12 bn by the completion of 2020. Having led the market in the recent past, DNA microarrays could continue with their dominance in terms of market share for the next few years. Geographically, the global market is foreseen to witness the rise of North America as a region with commanding growth.
Rising Requirement of Early Diagnosis of Various Types of Cancer Fuels Growth
Demand for array instruments is foretold to gain momentum in its rise due to increasing need for early detection and diagnosis of different cancer types. In addition to this, laboratory automation testifying a phenomenal rise because of the important role played by robotics could support the demand in the world array instruments market. Overall growth of the market could be stimulated by increasing applications of array instruments in various fields including life sciences and drug discovery.
Request A Sample-
Widely accepted technology, DNA microarrays are expected to gather pace in the world array instruments market on the basis of demand. They are traditionally employed in a number of applications. Furthermore, their enhanced accuracy and precision could push adoption in the coming years. In glycomics analysis, microarrays could be adopted as a powerful tool. The market is prophesied to gain impetus on the back of the rise of personalized medicine and targeted therapy.